Bionomics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BNOEF research report →
Price Chart
About the company
Bionomics Limited, an Australian clinical-stage biopharmaceutical company founded in 1996 and based in Eastwood, focuses on identifying and developing innovative drug candidates to address central nervous system conditions and various cancers. A significant experimental medicine in their pipeline is BNC210, a negative allosteric modulator targeting the a7 nicotinic acetylcholine receptor. This compound is currently undergoing a Phase 2 clinical trial for social anxiety disorder and a Phase 2b study for post-traumatic stress disorder (PTSD).
- CEO
- Spyridon Papapetropoulos
- IPO
- 2014
- HQ
- Eastwood, SA, AU
Get TickerSpark's AI analysis on BNOEF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.81M
- P/E
- -0.36
- PEG
- 0.01
- P/S
- -2.04
- P/B
- 0.73
- EV/EBITDA
- -0.09
- Div Yield
- 0.00%
- Gross Margin
- 104.75%
- Op Margin
- 230.73%
- Net Margin
- 271.97%
- ROE
- -113.35%
- ROIC
- -71.97%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $-434,000+97.7%
- Op Income
- $-17,892,376,000
- Net Income
- $-15,492,166,000-72936.6%
- EPS
- $-0.01+99.7%
- OCF Growth
- -3.3%
- FCF Growth
- -3.3%
- 52W High
- $0.06
- 52W Low
- $0.00
- 50D MA
- $0.01
- 200D MA
- $0.02
- Beta
- 1.84
- RSI (14)
- 46
- Avg Volume
- 91.84K
No earnings-call transcripts are available for BNOEF yet.
- Free Float
- 66.7%
- Shares Outstanding
- 1.47B
- Float Shares
- 980.03M
Our BNOEF coverage
Recent articles, reports, and earnings notes.
No research on BNOEF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BNOEF report →Bionomics Announces Supreme Court of New South Wales Approves Bionomics' Re-Domiciliation
globenewswire.com · Dec 16
Bionomics to Present at the 2024 American College of Neuropsychopharmacology Annual Meeting
globenewswire.com · Dec 3
Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States
globenewswire.com · Dec 2
Bionomics Provides an Update on Re-domiciliation via Scheme of Arrangement
globenewswire.com · Nov 8
Bionomics Receives Milestone Payment of AUS$1M from Carina Biotech for BNC101 Partnered Legacy Oncology Program
globenewswire.com · Nov 4
Bionomics to Present at the ThinkEquity Conference
globenewswire.com · Oct 23
Bionomics to Participate in the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
globenewswire.com · Oct 14
Bionomics Limited announces intention to re-domicile to the United States
globenewswire.com · Oct 1
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.